



METAPHARMACEUTICAL

N DE LOTE:

2101024

07/10/2024

Certificate of Analysis

Product name **MINOXIDIL EP/USP**

Product Code 17150
Batch Number 0024201942
Order 1240815
Quantity 350,000 KG

Manufacturing date 04/07/2024
Re-test date 01/05/2029
Certificate Nr. 100000035852
Batch Size 1.071,000 KG
Ref. Order 2024 - 1 / 187

Test	References	Specification	M.U.	Result
Appearance	EP	White or almost white crystalline powder		White crystalline powder
Identification (IR)	EP (2.2.24)/USP <197	IR spectrum conforms to standard		Complies
Identification (HPLC)	M> USP	Complies		Complies
Loss on drying	EP 2.2.32	<= 0,50	%	< 0,10
Residue on ignition	EP 2.4.14 USP < 281	<= 0,10	%	0,10
Appearance of solution Y6	EP(2.2.1)/(2.2.2)	Clear and not more coloured than Y6		Clear and not more coloured than Y6
Related substances (HPLC): 2,4-diamine-6-chloropyrimidine (Impurity B) + 2,4-diamino-5,6-dichloropyrimidine-3-oxide	EP 2.2.29	<= 0,100	%	not detectable
Related substances (HPLC): 2,4-Diamine-6-Piperidinpyrimidine (impurity E or deoxyminoxidil)	EP 2.2.29	<= 0,20	%	< LOD (0,007)
Related substances (HPLC): unspecified impurities	EP 2.2.29	<= 0,100	%	< LOQ (0,020)
Related substances (HPLC): total impurities by EP	EP 2.2.29	<= 0,300	%	<0,1% (0,02%)
Organic impurities (HPLC): Pyrimidine oxide analog	USP	<= 0,20	%	not detectable
Organic impurities (HPLC): Pyrimidine analog	USP	<= 0,20	%	not detectable
Organic impurities (HPLC): Deoxyminoxidil	USP	<= 0,20	%	< LOD (0,013)
Organic impurities (HPLC): Any individual unspecified impurity	USP	<= 0,10	%	< LOD (0,009)
Organic impurities (HPLC): Total impurities by USP	USP	<= 0,30	%	<0,1% (0,007%)
Assay (HPLC)	USP	97.0 - 103.0	%	100,1

Ivo Zanotti QC Manager Approved September 27, 2024	Laura Berra Qualified Person Released September 27, 2024
'Emission'	Laura Berra Qualified Person September 30, 2024



Certificate of Analysis

Product name **MINOXIDIL EP/USP**

Product Code 17150
Batch Number 0024201942
Order 1240815
Quantity 350,000 KG

Manufacturing date 04/07/2024
Re-test date 01/05/2029
Certificate Nr. 100000035852
Batch Size 1.071,000 KG
Ref. Order 2024 - 1 / 187

<u>Test</u>	<u>References</u>	<u>Specification</u>	<u>M.U.</u>	<u>Result</u>
(on dried basis)				
Assay (HClO ₂) (on dried basis)	EP (2.2.20)	99,0 - 101,0	%	100,1
Residual solvents (GC): acetone	Internal Method	<= 1000	ppm	< LOD (25)
Residual solvents (GC): Isopropyl Alcohol	Internal Method	<= 2000	ppm	< LOD (45)
Particle size	Internal Method	On customer request		On customer request

This batch was manufactured, packaged and tested in compliance with ICH Q7 and EU GMP Guideline Volume 4 Part II.

Manufacturing site of the Active Pharmaceutical Ingredient: Olon spa Mulazzano Plant.

Not to be used in sterile parenteral and sterile non-parenteral products.

Ivo Zanotti QC Manager Approved September 27, 2024	Laura Berra Qualified Person Released September 27, 2024		
'Emission'	Laura Berra	Qualified Person	September 30, 2024

Capitale Sociale € 40.000.000 i.v. - R.I. Milano Cod. Fisc. e P.IVA n. 08101100157 - R.E.A. Milano n. 1201640
Società Capogruppo P. & R. Principi Attivi S.p.A
Società con Socio unico - Strada Rivoltana km. 6/7 - 20053 Rodano (MI) ITALY - Capitale sociale € 1.200.000 i.v.- C.F. e P.IVA 11155530964